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Chinese herbal medicine has been commonly used in the treatment of postinfectious cough. The aim of this review is to
systematically evaluate the efficacy and safety of Chinese herbal medicine for postinfectious cough. An extensive search for RCTs
was performed using multiple electronic databases, supplemented with a manual search. All studies included were confirmed with
specific inclusion criteria. Methodological quality of each study was examined according to the Cochrane risk of bias assessment.
Quality of evidence was evaluated using rating approach developed by GRADE working group. The literature search yielded 352
results, of which 12 RCTs satisfied the inclusion criteria, offering moderate-to-high levels of evidence. Methodological quality was
considered high in three trials, while in the other nine studies the unclear risk of bias was in the majority. Findings suggested that,
compared with western conventional medicine or placebo, Chinese herbal medicine could effectively improve core symptoms of
postinfectious cough, act better and have earlier antitussive effect, and enhance patients’ quality of life. No serious adverse event
was reported.
1. Introduction
Patients who complain of a persistent cough lasting >3 weeks
but not >8 weeks after experiencing the acute symptoms of
an upper respiratory tract infection are considered to have a
postinfectious cough (PIC) [1]. PIC is supposed to be themost
common cause of subacute cough [2], which is distinguished
from the chronic cough by the duration of coughing [3].
For adults, retrospective studies of unselected patients with
a history of upper respiratory tract infection showed that
the frequency of PIC ranged from 11 to 25% [4], which
increased to the range from 25 to 50% during outbreaks of
atypical pathogens infections [5, 6]. Respiratory viruses, M.
pneumoniae, Chlamydophila pneumonia, and some specific
bacteria have been implicated in the cause of PIC [7, 8].
The pathogenesis of the PIC has not been clearly recognized.
It was frequently thought to be relevant to multiple factors
involving disruption of epithelial integrity, widespread airway
inflammation, and bronchial hyperresponsiveness [9–12].
Although PIC is self-limited and will usually resolve
on its own in time, persistent cough always incurs much
health troubles and economic miseries for patients and
their surroundings. Thus, medication therapy is imperative
sometimes. Up to now, optimal treatment of western con-
ventional medication (WCM) for patients with PIC is not
known [1]. Symptomatic therapeutic medications including
antihistamine, decongestant, and ipratropium bromide are
being commonly used. Besides, brief course of inhaled or oral
corticosteroids [13] has sometimes been administered in view
of airway inflammations. But corticosteroids were generally
used just in patients with severe paroxysms of PIC for their
remarkable side effects [1]. Central acting antitussive agent
such as codeine or dextromethorphan would be considered,
as a last resort, in those patients who are resistant to
other treatment approaches; however, there have been no
clinical trials conducted to support its effect [1]. In addition,
antibiotics are usually abused in treatment of PIC. Therefore,
research for optimal treatment of PIC is particularly needed
[14, 15].
TCM has unique understanding of PIC and has estab-
lished its own diagnosis and treatment approach. In TCM
theory system, PIC, equivalent to the category of exogenous
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cough, is caused by invasion of external evil factors (wind-
evil, cold-evil, summer-damp-evil, wet-evil, dryness-evil, and
fire-evil). These factors disturb or suppress Qi activity in
the lung, leading to acute cough. If things continue this
way, the lung-Qi would be damaged and unable to drive
evils out, leaving external evils lingering in the lung for a
long time. In this case, patients would suffer a fairly long
duration of cough. With thousands of years of experience,
TCM clinicians summarized the most common pathomech-
anism of PIC as “disorder Qi activity in the lung” due to
“wind-evil invading the lung.”The corresponding therapeutic
method is “dispelling wind and dispersing the lung-Qi.” PIC
is a disease with complex pathogenic conditions including
phlegm turbidity and deficiency of the lung-Yin. So flexible
treatment based on syndrome differentiation is important.
An increasing number of clinical trials on CHM for PIC
have been performed.This current systematic review aims to
collect the evidence from RCTs to evaluate the therapeutic
effect and safety of CHM in the management of PIC.
2. Methods
2.1. Research Protocol. All methods were performed accord-
ing to a predefined, unpublished protocol, which consisted
of the search databases, detailed research question, search
strategies, and eligibility criteria. The detailed research ques-
tion included study design, patient characteristics, interven-
tions, and outcomes.
2.2. Database and Search Strategies. Literature searches were
conducted to identify reports of randomized controlled trials
involving CHM for PIC in the following preliminary deter-
mined electronic databases: Chinese National Knowledge
Infrastructure (CNKI), Wanfang Database, EMBASE, MED-
LINE (PubMed), Cqvip Database, Google Scholar, Scholarly
and Academic Information Navigator (CiNii), and Cochrane
Library from inception to July 2013. Ongoing registered
clinical trials were searched on the website of Chinese clinical
trial registry (ChiCTR) (http://www.chictr.org/). Searches for
relevant conference proceedings, unpublished literature, and
studies (Table 1) included in previous relevant systematic
reviews were performed. Moreover, manual searches for
bibliographies of all retrieved literature sources were con-
ducted for additional references. No language restriction was
applied.
The following phrases and their derivatives or relevant
termswere utilized singly or in combination: “post-infectious
cough,” “subacute cough,” “cough post influenza,” “postvi-
ral cough,” “post-cold cough,” “whooping cough,” “Chinese
herbal medicine,” “traditional Chinese medicine,” and “ran-
domized controlled trial.” The search terms were modified
to adapt to different databases with a highly sensitive search
strategy developed by the Cochrane Collaboration [16]. We
contacted authors for further information or clarification.
Searching work was done by two reviewers (Wei Liu and
Hong-Li Jiang) independently. Searching results were cross-
checked for accuracy.
2.3. Inclusion Criteria
2.3.1. Types of Studies. All relevant randomized controlled tri-
als or quasirandomized controlled trials that were published
before July 20, 2013 were considered, regardless of blinding.
2.3.2. Types of Participants. Any patients with diagnosed and
existing PIC, of either gender, any profession or ethnicity, and
any ages ≥12, were included. Those without description of
diagnostic criteria but stated patients with definite PIC were
also considered.
2.3.3. Types of Interventions. Studies involving a comparison
between CHM alone or in combination with WCM and the
same WCM or placebo as controls were included. CHM
included herbal extracted product, Chinese patent medicine
(CPM), and self-modified herbal formula. CHM could be of
any dose, duration, dosage form, and route of administration.
Studies involving cointerventions of traditional extrapul-
monary therapies such as acupuncture, cupping, or point
application were excluded.
2.3.4. Outcomes. Primary outcomes measures were as fol-
lows: (1) cough symptom score, which consists of the
daytime-score and the nighttime-score, ranging from 0 to 6
[17]; (2) cough relief time, defined as both the daytime-score
and the nighttime-score ≤1, which lasted for 48 hours; (3)
cough disappearance time, defined as both of the daytime-
score and the nighttime-score = 0, which lasted for 48 hours.
Secondary outcome measures were as follows: (1) Obvious
effective rate, defined as reduced rate of symptoms score
≥70% according to theGuiding Principle of Clinical Research
on New Drugs of TCM [18, 19]; (2) quality-of-life (QoL)
score, evaluated using Cough-Specific Quality-of-Life Ques-
tionnaire (CQLQ) [20] or Leicester Cough Questionnaire
(LCQ) [21]; (3) adverse events.
2.4. Studies Selection and Data Extraction. Two reviewers
(Wei Liu and Hong-Li Jiang) independently screened the
titles and abstracts of searching results against prespecified
inclusion criteria to identify potential relevance that required
full texts for further identification. Disagreements were
resolved by consensus. All articles included were judged by
the third reviewer (Bing Mao).
Two reviewers (Wei Liu and Hong-Li Jiang) sys-
tematically extracted data regarding study design, demo-
graphic characteristics, interventions, and outcomemeasures
independently. Discrepancies were resolved by discussion
between the two reviewers or by consultation with the third
arbitration (Bing Mao).
2.5. Qualities Assessment. We used risk of bias assessment
tool recommended by the Cochrane Collaboration to address
the following six domains: random sequence generation, allo-
cation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data,
selective outcome reporting, and “other bias” [22]. The risk
of bias for each item was summarized as three levels: low,
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high, and unclear. The risk of bias graph was made using
RevMan 5.2 software.
We also used GRADE approach to assess the quality of
the evidence for each individual outcome. Besides within-
study limitations of design and execution (methodological
quality), the GRADE approach incorporates comprehensive
considerations of the following four factors: directness of evi-
dence, inconsistency of results, imprecision, and publication
bias [23, 24]. Accordingly, we graded the quality of evidence
as very low, low, moderate, or high.
The first reviewer (Wei Liu) performed the quality assess-
ments with supervision from the other two reviewers (Hong-
Li Jiang and Bing Mao).
2.6. Data Analysis. In this review, a formal meta-analysis
would not be conducted for the predicted large heterogeneity
across trials [25]. Therefore, a narrative synthesis approach
was applied.
3. Results
3.1. Description of Included Studies. The search strategies
came up with 352 potentially relevant citations. Twelve
trials involving 1289 subjects satisfied all the inclusion cri-
teria (Figure 1). One unpublished study [35] searched on
the website of ChiCTR was included (registration number
ChiCTR-TRC-12002297). Patients included in all studies
were explicitly diagnosed as having PIC according to the
nationwide unified western medicine diagnostic criteria [17]
or ACCP Evidence-Based Clinical Practice Guidelines. TCM
syndrome differentiation was identified based on the recog-
nized guiding principles [18, 38]. TCM syndrome of each
patient was specified in ten studies and it was defined as
“syndrome of wind evil invading the lung” in seven studies.
As to the interventions, two studies compared CHM with
placebo [33, 35], five studies compared CHMwithWCM [26,
29, 31, 34, 37], and two studies compared CHM adjuvantly
usedwithWCM to the sameWCMalone [27, 28], two studies
compared two CPMs [30, 32]. Three trials reported a follow-
up period to evaluate the sustained or subsequent effect of
interventions [31, 33, 35]. CHMs used in the studies included
were totally different. But nine of them [28–33, 35–37] were
prescribed based on the same TCM therapeutic principle of
“dispelling wind and dispersing the lung-Qi” (Table 2).
3.2. Quality Assessment of Included Studies. In general, the
unclear risk of bias is in the majority. Very limited informa-
tion was available in many studies to permit a judgment of
whether the risk of bias existed (Table 3).
Appropriate random component in the sequence gener-
ation process was described in six trials [30–33, 35, 36]. One
study [37] implemented a quasirandommethod by allocating
patients according to sequence number of visiting. In this
situation, patients’ assignments could possibly be foreseen,
which would introduce high selection bias.
Allocation concealment was presented in three trials
[32, 33, 35]. One study [27] only pointed “envelopes” but
did not specify whether they were sequentially numbered,
properly opaque, or sealed. Other studies failed to show
any information of allocation concealment. Thus, whether
the randomization was effectively conducted was doubtful,
leading to an unclear risk of selection bias.
Blinding was not addressed in most studies. Only three
studies [32, 33, 35] claimed to be double-blind and elaborated
the blinding method that was unlikely to be broken, con-
tributing to a sufficient protection against bias. One study [37]
stated single blind just in broad terms, so the performance
risk of bias was classified as “unclear.” Three studies [27, 29,
34] were open-label trials, and the patients’ knowledge of
interventions they received was likely to result in a high risk
of detection bias.
3.3. Quality of Evidence of Included Studies. The “GRADE
profiler” of the Cochrane Collaboration Network was used
to assess the individual outcome.The quality of evidence was
labeled as moderate to high (Table 4).
3.4. Outcome Measures of Included Studies. Forest plots were
used to show the statistical results of some outcomemeasures.
Two studies [35, 36] divided patients into three groups, so
each of them was regarded as two RCTs in the final analysis.
3.4.1. Cough Symptom Score. Cough symptom score was
reported in five studies. Two studies [26, 27] showed no
significant difference between bakumondo-to group and
WCM group at the last visit of view, but both of them found
that bakumondo-to group had amore quick antitussive effect.
Three studies [30, 31, 35] concluded significant difference
between the trial group and the control group (Figure 2).
3.4.2. Cough Relief Time. Seven trials selected cough relief
time as an outcome measure. For this indicator, six studies
demonstrated statistically significant difference between the
trial group and the control group [29, 30, 33–35, 37], indicat-
ing a more rapid cough relief effect of CHM, of which two
studies [33, 35] estimated cough relief time for each group
using Kaplan-Meier method (median cough relief time: T =
6 d, C = 7 d; log-rank test 𝑃 = 0.026 [33]; median cough relief
time:H= 4 d, L = 4 d, C = 6 d; log-rank test𝑃 < 0.001 [35]). In
the other study [32], significant difference between twoCPMs
(Su-huang Zhi-ke capsule and Zhi-ke Ning-sou capsule) was
not observed in statistical analysis (Figure 3).
3.4.3. Cough Disappearance Time. Cough disappearance
time was investigated in two researches. One study [35]
showed better effect favoring CHM groups and detected
statistical significance on difference across three groups
(median cough disappearance time:H= 8 d, L≥ 10 d, C≥ 10 d;
log-rank test 𝑃 < 0.001). The other study [32] demonstrated
the same effect of two CPMs (Su-huang Zhi-ke capsule and
Zhi-ke Ning-sou capsule) (MD = −0.11, 95% [0.83, 0.61]).
3.4.4. Obvious Effective Rate. Nine trials selected “effective
rate” (ER) as an outcomemeasurement. In these studies, “rate
ratio” (RR)was calculated as the ratio between the proportion
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Additional records identified
through hand searching (n = 3)
Duplication removals (n = 83)
Records screened for titles and
abstracts (n = 269)
Full-text articles assessed
for eligibility (n = 157)





















Records excluded (n = 112):
no outcomes required (n = 19);
case reports (n = 22);
not PIC (n = 57);
animal experiments (n = 11);
Records excluded (n = 145):
case-control studies (n = 8);
unavailable full-texts (n = 2);
not real rcts (n = 38);
not pic (n = 28);
reviews (n = 35);
cointerventions (n = 6);
Records identified through database and
website searching (n = 352): CNKI (n = 83);
Wanfang (n = 76); EMBASE (n = 57);
MEDLINE (n = 22): Cqvip (n = 72);
Google Scholar (n = 27); CiNii (n = 9);
clinical trial registry websites (n = 3)
case-control studies (n = 3)
incomplete statistical results (n = 4);
no detailed diagnose and patient-
inclusion criteria (n = 24)
Figure 1: Process of study search and selection.
Study 
Fujimori et al., 2001 
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Figure 2: Cough symptom score analysis.
of responders in the trial group and the proportion of respon-
ders in the control group. Responders were defined as those
patients with an improvement rate of symptoms score ≥70%.
For this indicator, eight studies were statistically significant,
showing that CHM can improve clinical core symptoms of
PIC [28, 30, 32–37]. The same effect of CHM and WCM was
reported in one study [29] (Figure 4).
3.4.5. Quality-of-Life Score. Quality-of-life (QoL) evaluation
was conducted in two studies. Both of them showed that
CHM possessed a better effect in improving patients’ quality
of life. One study [35] calculated CQLQ total score and
demonstrated significant difference across groups (𝑃 <
0.00001, MD = −8.34, 95% [−11.63, −5.05]). The other study
[30] recorded physical, psychological, and social domains
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CHM Control Risk ratio Risk ratio
M-H, fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours (CHM) Favours (control)
Figure 4: Obvious effective rate analysis.
of LCQ,and difference of post treatment score for the three
domains between a self-modified decoction (Qing-fei Zhi-
ke decoction) and a CPM (Jizhi syrup) was statistically sig-
nificant (MD and 95% for physical, psychological, and social
domains, respectively:MD=−0.90, 95%[−1.01, −0.80];MD=
−3.00, 95%[−3.08, −2.92]; MD = −0.72, 95%[−0.87, −0.56]).
3.5. Adverse Events. In general, CHM was claimed to have
fewer side effects compared withWCM. Adverse events were
mentioned in eleven studies. Four studies [25, 28, 29, 33]
reported that no adverse events were observed at the end
of treatment. In seven studies [26, 30–32, 34–36], various
adverse events were reported for 49 patients in the control
group and for 114 patients in the trial group. All the adverse
reactions were mild and did not affect results estimation
(Figure 5).
4. Discussion
Broadly speaking, findings of this current review suggested
that CHM may have potential positive clinical effect in the
treatment of PIC, and the outcome evidence was relatively
optimistic for us to make further research to draw a confir-
mative conclusion.
Three included studies [32, 33, 35] were well-designed,
leading to favorable methodological quality and robustness
of results. Besides, reporting form and content of these
three articles were comprehensive and they basically met the
international criteria of CONSORT statement [39]. In other
studies, limitations commonly concerned the issue of alloca-
tion concealment and blinding. Just like most of the TCM
clinical trials, allocation concealment was not reported or not
appropriately put into effect in most studies in this review.
Only two studies [33, 35] were double-blind and placebo-
controlled. Both of them explicitly claimed that outcome
assessors and data analyzers were definitely unconscious of
interventions that patients received. Placebo is considered
as a welcome and reasonable control for effective estimation
of CHM [40, 41], because CHM is considered to possess
a potential psychological positive effect which is similar to
placebo. So if intervention other than placebo is applied as
control, the placebo-like effect of CHM may bring out false
or exaggerated positive results in favor of the trial group.
Imperfections of included studies also lie in the common
absence of sample size calculation. Only three studies [32, 33,
35] estimated sample size. Two studies [26, 27] recruited less
than 30 cases in each group, so it was not ensured whether
they could provide enough power to detect the difference
between groups. In addition, a small sample also might cause

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































12 Evidence-Based Complementary and Alternative Medicine
An, 2002 ?
Fujimori et al., 2001 ?
Huang, 2009 –
Irifune et al., 2011 ?






Wu et al., 2011 +














































































































































































































Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0 25 50 75 100
Low risk of bias
Unclear risk of bias
High risk of bias
(%)
(b)
Figure 5: (a) Risk of bias summary: review authors’ judgements about each risk of bias item for each included study, dash sign: high risk of
bias, plus sign: low risk of bias, question mark sign: unclear risk of bias; (b) risk of bias graph: review of authors’ judgements about each risk
of bias item presented as percentages across all included studies.
exaggerated difference between groups. Therefore, outcomes
in this case should be regarded with caution.
Although the formulas used in the trials included in this
review were not completely equivalent, nine of them [28–33,
35–37] were prescribed based on the same fundamental TCM
therapeutic principle of “dispelling wind and dispersing the
lung-Qi.” Ephedra, Platycodon grandiflorus, Folium perilla,
Almond, and Schizonepeta tenuifolia were usually used in
prescriptions with this function. The corresponding TCM
syndrome of patients is “wind evil attacking the lung”, which
Evidence-Based Complementary and Alternative Medicine 13
is considered as the most common syndrome in patients
with PIC. In addition, TCM therapeutic principles such
as nourishing the lung-Yin, resolving phlegm, expelling
cold, or eliminating heat were also commonly used for
PIC.
Most studies implied good safety of CHM. However,
some results should be treated with prudence because only
three studies [27, 33, 35] judged the definite relevance
between adverse events and corresponding interventions.
As a significant complementary and alternative therapeutic
method, TCM is traditionally regarded as natural with fewer
side effects. Thus, some researchers tend to pay less attention
to safety of CHM. But since the toxicological risks of CHM
have been observed in many researches [42], more emphasis
should be placed on this issue.
In this review, only four studies [26, 27, 33, 35] declared
ethical approval and only one study [35] completed clinical
trial registration on a publicly accessible database before
the trial was set about. Hence, compliance with ethical
guideline and trial registration should be addressed in further
researches to eventually strengthen the effectiveness and
value of scientific evidence.
Althoughmost of the studies in this review authoritatively
recommended CHM for PIC, it is impossible to conduct a
meaningful meta-analysis to prove the conclusion. Clinical
investigators have to consider repeating studies with the same
CHM for a powerfully statistical proved conclusion. Decoc-
tion, as a complex mixture, is usually prepared artificially.
Therefore, the processes of decoction manufacturing and
decoction administeration are unlikely to realize quality-and-
quantity control. Accordingly, the consistency of decoction
throughout the whole treatment course is suspected. In
addition, if decoction is used as intervention in a research,
blinding method is difficult to be implemented for it seems
impossible to produce a simulation. Thus, prepared drugs
formulated as granules, tables, pills, or capsules are in need
to reduce bias in TCM clinical trials.
5. Conclusion
Findings suggest that CHM may effectively improve core
symptoms of PIC, act better and have earlier antitussive
effect, and enhance patients’ quality of life. CHM is rela-
tively safe and well tolerated without serious side effects.
The most common syndrome of patients with PIC is “syn-
drome of wind evil invading the lung”; correspondingly,
“dispelling wind and dispersing the lung-Qi” is the com-
monest TCM therapeutic principle for PIC. Since some of
the studies included in this review were well-designed and
comprehensively reported, various limitations still existed.
Therefore, confirmative conclusions are not allowed. But
current evidence is promising for clinical investigators to
do further in-depth researches. Larger-scale, multicentre,
placebo-controlled studies for diverse populations are defi-
nitely welcomed. Action mechanism of CHM in treatment of
PIC, which has been poorly known, needs to be researched
to prove the effectiveness and safety of CHM in a more
convincing and essential manner.
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